Genetic Approaches To Identifying Novel Osteoporosis Drug Targets
Author:
- 14 August 2015
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 116 (10) , 2139-2145
Abstract
During the past two decades effective drugs for treating osteoporosis have been developed, including anti‐resorptives inhibiting bone resorption (estrogens, the SERM raloxifene, four bisphosphonates, RANKL inhibitor denosumab) and the anabolic bone forming daily injectable peptide teriparatide. Two potential drugs (odanacatib and romosozumab) are in late stage clinical development. The most pressing unmet need is for orally active anabolic drugs. This review describes the basic biological studies involved in developing these drugs, including the animal models employed for osteoporosis drug development. The genomics revolution continues to identify potential novel osteoporosis drug targets. Studies include human GWAS studies and identification of mutant genes in subjects having abnormal bone mass, mouse QTL and gene knockouts, and gene expression studies. Multiple lines of evidence indicate that Wnt signaling plays a major role in regulating bone formation and continued study of this complex pathway is likely to lead to key discoveries. In addition to the classic Wnt signaling targets DKK1 and sclerostin, LRP4, LRP5/LRP6, SFRP4, WNT16, and NOTUM can potentially be targeted to modulate Wnt signaling. Next‐generation whole genome and exome sequencing, RNA‐sequencing and CRISPR/CAS9 gene editing are new experimental techniques contributing to understanding the genome. The International Knockout Mouse Consortium efforts to knockout and phenotype all mouse genes are poised to accelerate. Accumulating knowledge will focus attention on readily accessible databases (Big Data). Efforts are underway by the International Bone and Mineral Society to develop an annotated Skeletome database providing information on all genes directly influencing bone mass, architecture, mineralization or strength. J. Cell. Biochem. 116: 2139–2145, 2015.Keywords
This publication has 53 references indexed in Scilit:
- Hunting human disease genes: lessons from the past, challenges for the futureHuman Genetics, 2013
- Next-generation sequencing for disorders of low and high bone mineral densityOsteoporosis International, 2013
- Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loadingBone, 2012
- ‘Sink or swim’: an evaluation of the clinical characteristics of individuals with high bone massOsteoporosis International, 2011
- Nosology and classification of genetic skeletal disorders: 2010 revisionAmerican Journal of Medical Genetics Part A, 2011
- PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodelingJournal of Bone and Mineral Research, 2010
- Control of Bone Mass and Remodeling by PTH Receptor Signaling in OsteocytesPLOS ONE, 2008
- LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk FactorsScience, 2007
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- Lessons from Osteopetrotic Mutations in Animals: Impact on Our Current Understanding of Osteoclast BiologyCritical Reviews™ in Eukaryotic Gene Expression, 2005